Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy

P. S. Randhawa, A. C. Tsamandas, M. Magnone, M. Jordan, R. Shapiro, T. E. Starzl, A. J. Demetris

Research output: Contribution to journalArticlepeer-review

69 Scopus citations


FK506 (Tacrolimus) recently has been shown to be an effective immunosuppressant after renal transplantation. It is associated with less hypertension, hypercholesterolemia and steroid use compared with cyclosporine. We report 10 patients on FK506 who showed fibrin thrombi within the glomerular capillaries and/or arterioles at renal allograft biopsy. These biopsies were generally performed to assess increasing serum creatinine levels; laboratory evidence of hemolytic uremic syndrome was present in one instance. Plasma or whole blood FK506 levels were elevated in eight of 10 cases. Reduction of immunosuppression led to clinical improvement or biopsy- proven resolution of thrombi in all cases. These observations suggest that FK506 may occasionally produce microvascular changes in the renal allograft. The estimated incidence of this occurrence (1%) is comparable with that reported with cyclosporine (3%).

Original languageEnglish
Pages (from-to)306-312
Number of pages7
JournalAmerican Journal of Surgical Pathology
Issue number3
StatePublished - Mar 1996
Externally publishedYes


  • Allografts
  • FK506
  • Kidney
  • Tacrolimus
  • Thrombi
  • Toxicity


Dive into the research topics of 'Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy'. Together they form a unique fingerprint.

Cite this